ArticleFrontiers in medicine2026
Reduced heart rate variability is associated with disease severity in AL amyloidosis: a retrospective cohort study.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Autonomic nervous system involvement is common in systemic amyloidosis, yet the clinical relevance of heart rate variability (HRV) in immunoglobulin light-chain (AL) amyloidosis remains incompletely defined. Methods: In this retrospective cohort study, 56 patients with biopsy-proven AL amyloidosis and 33 age- and sex-comparable healthy controls underwent 24 h Holter monitoring. Time- and frequency-domain HRV parameters were recorded. Associations of HRV with cardiac involvement assessed by cardiac magnetic resonance (CMR), Mayo 2004 stage, and short-term treatment response were evaluated using group comparisons and multivariable regression. Results: Compared with controls, patients with AL amyloidosis had significantly higher mean heart rate and lower SDNN, total power (TP), and all frequency-domain components (ULF, VLF, LF, and HF) (all Conclusion: Reduced HRV is a prominent feature of AL amyloidosis and is independently associated with Mayo stage after adjustment for cardiac biomarkers. These findings position HRV as a non-invasive marker of autonomic involvement that complements established cardiac biomarkers in characterising disease severity in AL amyloidosis; whether this translates into independent prognostic value requires evaluation in prospective outcome studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.